A
Long-Acting Injectables (LAIs) are a major treatment modality for schizophrenia, especially in patients with non-adherence to oral medication or recurrent relapses. Here’s a concise, clinically focused overview:
💉 LAIs in Schizophrenia: Overview
LAIs are antipsychotic medications formulated for intramuscular injection, with effects lasting 2 to 12 weeks, depending on the drug.
🎯 Why Use LAIs?
| Benefit | Clinical Impact |
|---|---|
| ✔ Improves adherence | Reduces relapse and hospitalization |
| ✔ Steady drug levels | Minimizes peaks/troughs and side effects |
| ✔ Long dosing intervals | Better for patients with poor insight |
| ✔ Early detection of non-adherence | Missed appointments = red flag |
🧠 Who Are LAIs Recommended For?
-
Recurrent relapses due to non-compliance
-
Poor insight into illness
-
Patients preferring less frequent dosing
-
First-episode psychosis (in select patients)
-
History of violence or self-neglect when unmedicated
🧪 Common LAIs by Antipsychotic Type
🧊 First-Generation (Typical) LAIs
| Drug | Dosing Interval | Notes |
|---|---|---|
| Haloperidol decanoate | Every 4 weeks | Start low; EPS risk |
| Fluphenazine decanoate | Every 2–3 weeks | High EPS, less used now |
💊 Second-Generation (Atypical) LAIs
| Drug | Dosing | Notes |
|---|---|---|
| Risperidone LAI (Risperdal Consta) | Every 2 weeks | Requires oral overlap for ~3 weeks |
| Paliperidone palmitate (Invega Sustenna/Trinza) | Monthly / every 3 months | No oral overlap; preferred for stable patients |
| Aripiprazole LAI (Abilify Maintena/Aristada) | Monthly / 6-week options | Needs oral overlap; activating profile |
| Olanzapine LAI (Zyprexa Relprevv) | Every 2–4 weeks | Rare but serious post-injection delirium/sedation syndrome (requires observation after injection) |
⚠️ Considerations & Side Effects
-
Injection site reactions
-
Extrapyramidal symptoms (EPS) (more with FGAs)
-
Sedation, weight gain, metabolic syndrome (especially SGAs)
-
Post-injection monitoring (e.g., Zyprexa Relprevv requires 3 hours)
🔄 Initiation Protocols
-
Some LAIs require a test dose or oral supplementation during the first weeks
-
Assess for tolerability to oral form before initiating LAI
-
Educate patients about delayed onset of action
📊 Clinical Outcomes
-
Reduced hospital readmissions
-
Lower rates of symptom relapse
-
Better functional outcomes when adherence is sustained
-
Particularly effective in early intervention if used proactively
✅ Summary
| Feature | LAIs |
|---|---|
| What? | Long-acting injectable antipsychotics |
| Who? | Schizophrenia patients with adherence issues or multiple relapses |
| Benefits | Improves compliance, reduces relapse, maintains stability |
| Caution | Monitor side effects, ensure proper initiation protocol |
Would you like:
-
A decision algorithm for choosing an LAI?
-
Comparison table of side effects across LAIs?
-
LAI use in first-episode psychosis or treatment-resistant schizophrenia?
No comments:
Post a Comment